Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials

por Yun, Seongseok, Vincelette, Nicole D., Green, Myke R., Wahner Hendrickson, Andrea E., Abraham, Ivo
Publicado 2016

Parental health in fellowship trainees: Fellows’ satisfaction with current policies and interest in innovation

por Marshall, Ariela L, Dines, Virginia, Wahner Hendrickson, Andrea, Warsame, Rahma, Thanarajasingam, Gita, Thompson, Carrie, Petterson, Tanya, Wolanskyj-Spinner, Alexandra
Publicado 2020

An unusual case of aggressive malignant spread of epithelioid hemangioendothelioma

por Hickman, Ashley D, Bezerra, Evandro D, Roden, Anja C, Houdek, Matthew T, Barlow, Jonathan D, Robinson, Steven I, Wahner Hendrickson, Andrea E
Publicado 2021

Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization

por Ray, Upasana, Roy, Debarshi, Jin, Ling, Thirusangu, Prabhu, Staub, Julie, Xiao, Yinan, Kalogera, Eleftheria, Wahner Hendrickson, Andrea E., Cullen, Grace D., Goergen, Krista, Oberg, Ann L., Shridhar, Viji
Publicado 2021

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

por Colon-Otero, Gerardo, Zanfagnin, Valentina, Hou, Xiaonan, Foster, Nathan R, Asmus, Erik J, Wahner Hendrickson, Andrea, Jatoi, Aminah, Block, Matthew S, Langstraat, Carrie L, Glaser, Gretchen E, Dinh, Tri A, Robertson, Matthew W, Camoriano, John K, Butler, Kristina A, Copland, John A, Weroha, S John
Publicado 2020

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting

por Oberg, Ann L., Heinzen, Ethan P., Hou, Xiaonan, Al Hilli, Mariam M., Hurley, Rachel M., Wahner Hendrickson, Andrea E., Goergen, Krista M., Larson, Melissa C., Becker, Marc A., Eckel-Passow, Jeanette E., Maurer, Matthew J., Kaufmann, Scott H., Haluska, Paul, Weroha, S. John
Publicado 2021

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (K...

por You, Benoit, Purdy, Christopher, Copeland, Larry J., Swisher, Elizabeth M., Bookman, Michael A., Fleming, Gini, Coleman, Robert, Randall, Leslie M., Tewari, Krishnansu S., Monk, Bradley J., Mannel, Robert S., Walker, Joan L., Cappuccini, Fabio, Cohn, David, Muzaffar, Mahvish, Mutch, David, Wahner-Hendrickson, Andrea, Martin, Lainie, Colomban, Olivier, Burger, Robert A.
Publicado 2022

CHFR and Paclitaxel Sensitivity of Ovarian Cancer

por Wahner Hendrickson, Andrea E., Visscher, Daniel W., Hou, Xiaonan, Goergen, Krista M., Atkinson, Hunter J., Beito, Thomas G., Negron, Vivian, Lingle, Wilma L., Bruzek, Amy K., Hurley, Rachel M., Wagner, Jill M., Flatten, Karen S., Peterson, Kevin L., Schneider, Paula A., Larson, Melissa C., Maurer, Matthew J., Kalli, Kimberly R., Oberg, Ann L., Weroha, S. John, Kaufmann, Scott H.
Publicado 2021

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

por Block, Matthew S., Dietz, Allan B., Gustafson, Michael P., Kalli, Kimberly R., Erskine, Courtney L., Youssef, Bahaaeldin, Vijay, Geraldine V., Allred, Jacob B., Pavelko, Kevin D., Strausbauch, Michael A., Lin, Yi, Grudem, Megan E., Jatoi, Aminah, Klampe, Carolyn M., Wahner-Hendrickson, Andrea E., Weroha, S. John, Glaser, Gretchen E., Kumar, Amanika, Langstraat, Carrie L., Solseth, Mary L., Deeds, Michael C., Knutson, Keith L., Cannon, Martin J.
Publicado 2020

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

por Swisher, Elizabeth M., Kwan, Tanya T., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L., Aghajanian, Carol, Konecny, Gottfried E., O’Malley, David M., Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-may, Wahner Hendrickson, Andrea E., Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S., Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H., Elvin, Julia A., Lin, Douglas I., Chambers, Setsuko K., Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L., Lin, Kevin K., McNeish, Iain A.
Publicado 2021

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

por Hurley, Rachel M, McGehee, Cordelia D, Nesic, Ksenija, Correia, Cristina, Weiskittel, Taylor M, Kelly, Rebecca L, Venkatachalam, Annapoorna, Hou, Xiaonan, Pathoulas, Nicholas M, Meng, X Wei, Kondrashova, Olga, Radke, Marc R, Schneider, Paula A, Flatten, Karen S, Peterson, Kevin L, Becker, Marc A, Wong, Ee Ming, Southey, Melissa S, Dobrovic, Alexander, Lin, Kevin K, Harding, Thomas C, McNeish, Iain, Ross, Christian A, Wagner, Jill M, Wakefield, Matthew J, Scott, Clare L, Haluska, Paul, Wahner Hendrickson, Andrea E, Karnitz, Larry M, Swisher, Elizabeth M, Li, Hu, Weroha, S John, Kaufmann, Scott H
Publicado 2021